Elaine Hylek

Summary

Affiliation: Boston University
Country: USA

Publications

  1. ncbi request reprint Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes
    Elaine M Hylek
    Boston University Medical Center, Boston, Massachusetts Electronic address
    J Am Coll Cardiol 63:2141-7. 2014
  2. ncbi request reprint Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation
    Elaine M Hylek
    Elaine M Hylek, MD, MPH, Boston University School of Medicine, Section of General Internal Medicine, 801 Massachusetts Avenue, 2nd fl suite, Boston, MA 02118, USA, Tel 1 617 414 3743, E mail
    Thromb Haemost 111:783-8. 2014
  3. doi request reprint Anticoagulation therapy for atrial fibrillation
    Elaine M Hylek
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Semin Thromb Hemost 39:147-52. 2013
  4. doi request reprint Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement
    Elaine M Hylek
    Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
    J Thromb Thrombolysis 35:333-5. 2013
  5. ncbi request reprint DU-176b, an oral, direct Factor Xa antagonist
    Elaine Hylek
    Boston University Medical Center, Department of Medicine, 91 East Concord Street, Suite 200, Boston, MA 02118, USA
    Curr Opin Investig Drugs 8:778-83. 2007
  6. ncbi request reprint Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation
    Elaine M Hylek
    Research Unit, Section of General Internal Medicine, Boston University School of Medicine, Boston Medical Center, 91 East Concord St, Suite 200, Boston, MA 02118, USA
    Circulation 115:2689-96. 2007
  7. doi request reprint Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation
    Elaine M Hylek
    Research Unit Section of General Internal Medicine and Clinical Epidemiology Unit, Boston University School of Medicine, 801 Massachusetts Avenue, 2nd Floor, Boston, MA 02118, USA
    Thromb Haemost 100:16-7. 2008
  8. ncbi request reprint Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V
    Elaine M Hylek
    Department of Medicine, Research Unit, Section of General Internal Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Stroke 39:3009-14. 2008
  9. doi request reprint The need for new oral anticoagulants in clinical practice
    Elaine M Hylek
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Cardiovasc Med (Hagerstown) 10:605-9. 2009
  10. doi request reprint Antithrombotic prophylaxis in elderly patients with atrial fibrillation
    Elaine M Hylek
    Department of Medicine, Research Unit Section of General Internal Medicine, Boston University Medical Center, Boston, Massachusetts 02118, USA
    Semin Thromb Hemost 35:548-53. 2009

Detail Information

Publications38

  1. ncbi request reprint Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes
    Elaine M Hylek
    Boston University Medical Center, Boston, Massachusetts Electronic address
    J Am Coll Cardiol 63:2141-7. 2014
    ....
  2. ncbi request reprint Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation
    Elaine M Hylek
    Elaine M Hylek, MD, MPH, Boston University School of Medicine, Section of General Internal Medicine, 801 Massachusetts Avenue, 2nd fl suite, Boston, MA 02118, USA, Tel 1 617 414 3743, E mail
    Thromb Haemost 111:783-8. 2014
    ....
  3. doi request reprint Anticoagulation therapy for atrial fibrillation
    Elaine M Hylek
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Semin Thromb Hemost 39:147-52. 2013
    ..Translating the efficacy of clinical trials into effective use of these novel agents in clinical practice will require an understanding of their pharmacokinetic profiles, dose selection, and management in select clinical situations...
  4. doi request reprint Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement
    Elaine M Hylek
    Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
    J Thromb Thrombolysis 35:333-5. 2013
    ..Targeted strategies to improve TTR are urgently needed...
  5. ncbi request reprint DU-176b, an oral, direct Factor Xa antagonist
    Elaine Hylek
    Boston University Medical Center, Department of Medicine, 91 East Concord Street, Suite 200, Boston, MA 02118, USA
    Curr Opin Investig Drugs 8:778-83. 2007
    ..By January 2005, phase II studies had begun in the US and Europe, and by March 2006, phase II studies had begun in Japan. Phase II trials for the prevention of thromboembolism were ongoing in mid 2007...
  6. ncbi request reprint Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation
    Elaine M Hylek
    Research Unit, Section of General Internal Medicine, Boston University School of Medicine, Boston Medical Center, 91 East Concord St, Suite 200, Boston, MA 02118, USA
    Circulation 115:2689-96. 2007
    ..We sought to define the tolerability of warfarin among an elderly inception cohort with atrial fibrillation...
  7. doi request reprint Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation
    Elaine M Hylek
    Research Unit Section of General Internal Medicine and Clinical Epidemiology Unit, Boston University School of Medicine, 801 Massachusetts Avenue, 2nd Floor, Boston, MA 02118, USA
    Thromb Haemost 100:16-7. 2008
  8. ncbi request reprint Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V
    Elaine M Hylek
    Department of Medicine, Research Unit, Section of General Internal Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Stroke 39:3009-14. 2008
    ..We sought to determine if differences in baseline characteristics, use of potentially risk-modifying medications, or anticoagulation control help to explain the lower risk of stroke among warfarin-treated patients in SPORTIF V...
  9. doi request reprint The need for new oral anticoagulants in clinical practice
    Elaine M Hylek
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Cardiovasc Med (Hagerstown) 10:605-9. 2009
    ..As a result, there is a pressing need for convenient new, well-tolerated and effective oral anticoagulants that do not require frequent dose adjustment and routine coagulation monitoring...
  10. doi request reprint Antithrombotic prophylaxis in elderly patients with atrial fibrillation
    Elaine M Hylek
    Department of Medicine, Research Unit Section of General Internal Medicine, Boston University Medical Center, Boston, Massachusetts 02118, USA
    Semin Thromb Hemost 35:548-53. 2009
    ..An understanding of the pathological changes that predispose to hemorrhage, hazards of polypharmacy, and factors that contribute to variability in dose response will facilitate a more informed use of these medications in clinical care...
  11. ncbi request reprint Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation
    Elaine M Hylek
    Department of Medicine, Boston University School of Medicine, MA 02118, USA
    Stroke 37:1075-80. 2006
    ..In addition to baseline characteristics, we sought to define the physician-cited reason for not prescribing warfarin for each patient...
  12. pmc Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
    Benjamin A Steinberg
    From the Duke University Medical Center, Durham, NC B A S, J P P, E D P Duke Clinical Research Institute, Durham, NC B A S, S K, L T, J P P, E D P UCLA School of Medicine, Los Angeles, CA G C F Boston University School of Medicine, Boston, MA E H New York University School of Medicine, Lenox Hill Hospital, New York, NY J A Kaiser Permanente, Oakland, CA A S G Janssen Pharmaceuticals, Inc, Raritan, NJ P C Lankenau Institute for Medical Research, Wynnewood, PA P K Mayo Clinic, Rochester, MN B J G Stanford University School of Medicine, Palo Alto, CA K W M and Harvard Medical School and Massachusetts General Hospital, Boston, MA D E S
    Circulation 129:2005-12. 2014
    ..Although empirical models have been developed to predict such risks, the degree to which these coincide with clinicians' estimates is unclear...
  13. ncbi request reprint Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Jack Ansell
    Department of Medicine, Boston University Medical Center, 88 East Newton Street, Boston, MA 02118, USA
    Chest 133:160S-198S. 2008
    ..Patient self-monitoring or self-management, however, is a choice made by patients and physicians that depends on many factors. We suggest that such therapeutic management be implemented where suitable (Grade 2B)...
  14. ncbi request reprint The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Jack Ansell
    Department of Medicine, Boston University Medical Center, 88 E Newton St, Boston, MA 02118, USA
    Chest 126:204S-233S. 2004
    ....
  15. pmc Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry
    Benjamin A Steinberg
    MPH, Duke University Medical Center and Duke Clinical Research Institute, 2400 Pratt St, Ste 7009, Durham, NC 27705, USA
    Circulation 128:721-8. 2013
    ..We assessed concomitant ASA use and its association with clinical outcomes among AF patients treated with OAC...
  16. ncbi request reprint Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population
    David Garcia
    Department of Medicine, Division of General Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA
    Chest 127:2049-56. 2005
    ....
  17. ncbi request reprint Measuring quality of oral anticoagulation care: extending quality measurement to a new field
    Adam J Rose
    Center for Health Quality, Outcomes and Economic Research, Bedford VA Medical Center, Bedford, MA, USA
    Jt Comm J Qual Patient Saf 35:146-55. 2009
    ..To address this gap in the literature, a MEDLINE search was conducted for all papers relevant to possible quality measures in oral anticoagulation care, including measures of structure, process, and outcomes of care...
  18. ncbi request reprint The risk of hemorrhage among patients with warfarin-associated coagulopathy
    David A Garcia
    Department of Medicine, University of New Mexico, Albuquerque, New Mexico, USA
    J Am Coll Cardiol 47:804-8. 2006
    ..Among warfarin-treated patients with international normalized ratio (INR) >5, we sought to determine the risk of major bleeding within 30 days...
  19. doi request reprint Epidemiology of subtherapeutic anticoagulation in the United States
    Adam J Rose
    Center for Health Quality, Outcomes, and Economic Research, Bedford VA Medical Center, Bedford, MA 01730, USA
    Circ Cardiovasc Qual Outcomes 2:591-7. 2009
    ..Low international normalized ratio (INR; <or=1.5) increases risk for thromboembolism. However, little is known about the epidemiology of low INR...
  20. pmc Effectiveness of warfarin among patients with cancer
    Adam J Rose
    Department of Medicine, Research Unit Section of General Internal Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA 02118 2644, USA
    J Gen Intern Med 22:997-1002. 2007
    ..Is this also the case when cancer patients are anticoagulated for other indications?..
  21. doi request reprint Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA)
    Adam J Rose
    Center for Health Quality, Outcomes, and Economic Research, Bedford VA Medical Center, 200 Springs Road, Bedford, MA 01730, USA
    Circ Cardiovasc Qual Outcomes 4:22-9. 2011
    ..Our objective was to profile site performance in the Veterans Health Administration (VA) using risk-adjusted percent time in therapeutic range (TTR)...
  22. ncbi request reprint Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis
    Elaine M Hylek
    General Medicine Division Clinical Epidemiology Unit, Ninth Floor, Massachusetts General Hospital, 50 Staniford St, Boston, MA 02114, USA
    Arch Intern Med 163:621-7. 2003
    ..We sought to assess the real-world course of transition from heparin to warfarin in hospitalized patients undergoing anticoagulation therapy for acute venous or arterial thrombosis at our medical center...
  23. ncbi request reprint Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors
    Elaine M Hylek
    Harvard Medical School, General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
    Semin Vasc Med 3:271-8. 2003
    ....
  24. ncbi request reprint Trends in anticoagulation management across community-based practices in the United States: the Anticoagulation Consortium to Improve Outcomes Nationally (ACTION) study
    Elaine M Hylek
    Department of Medicine, General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Thromb Thrombolysis 16:83-6. 2003
    ..This report describes the methodology and preliminary results. Analysis is ongoing, and full results will be reported in the future...
  25. pmc The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation
    Carmella Evans-Molina
    Department of Medicine, Division of Endocrinology and Metabolism, University of Virginia, Charlottesville, Virginia, USA
    J Am Geriatr Soc 55:1038-43. 2007
    ..To compare prescription drug cost savings under the most commonly selected Medicare Part D prescription plan in 2006 with savings under the Medicare standard benefit and with drug costs assuming no coverage in an elderly cohort of patients...
  26. ncbi request reprint Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation
    Elaine M Hylek
    General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    N Engl J Med 349:1019-26. 2003
    ..0 or greater. The effect of the intensity of oral anticoagulation on the severity of atrial fibrillation-related stroke is not known but is central to the choice of the target INR...
  27. ncbi request reprint Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
    Alan S Go
    Division of Research, Kaiser Permanente of Northern California, Oakland, CA, USA
    J Thromb Thrombolysis 15:41-6. 2003
    ..Since atrial and venous pressures are similar, genetic variants that promote venous thromboembolism may increase the risk of atrial thrombi and subsequent stroke in atrial fibrillation...
  28. ncbi request reprint Antithrombotic therapy in atrial fibrillation
    David A Garcia
    Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA
    Clin Geriatr Med 22:155-66, x. 2006
    ....
  29. ncbi request reprint Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?
    Alan S Go
    Division of Research, Kaiser Permanente of Northern California, Oakland, CA 94612, USA
    JAMA 290:2685-92. 2003
    ..Warfarin has been shown to be highly efficacious for preventing thromboembolism in atrial fibrillation in randomized trials, but its effectiveness and safety in clinical practice is less clear...
  30. pmc Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study
    Margaret C Fang
    University of California at San Francisco, 94143, USA
    J Am Geriatr Soc 54:1231-6. 2006
    ..To assess whether older age is independently associated with hemorrhage risk in patients with atrial fibrillation, whether or not they are taking warfarin therapy...
  31. pmc Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study
    Margaret C Fang
    University of California, San Francisco, CA 94143, USA
    Circulation 112:1687-91. 2005
    ..We examined data from a large contemporary cohort of AF patients to address this question...
  32. pmc Death and disability from warfarin-associated intracranial and extracranial hemorrhages
    Margaret C Fang
    The Department of Medicine, Hospitalist Group, University of California, San Francisco, Calif 94143, USA
    Am J Med 120:700-5. 2007
    ..We examined the rates of death and disability resulting from warfarin-associated intracranial and extracranial hemorrhages in a large cohort of patients with atrial fibrillation...
  33. ncbi request reprint Methodological considerations for interpretation of rates of major haemorrhage in studies of anticoagulant therapy for atrial fibrillation
    Elaine M Hylek
    Europace 10:3-5. 2008
  34. doi request reprint Risk of thromboembolism with short-term interruption of warfarin therapy
    David A Garcia
    Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
    Arch Intern Med 168:63-9. 2008
    ..We aimed to assess the frequency of thromboembolism and bleeding within a large cohort of patients whose warfarin therapy was temporarily withheld for an outpatient invasive procedure...
  35. ncbi request reprint Genetic testing for warfarin dosing? Not yet ready for prime time
    Henry I Bussey
    Pharmacotherapy 28:141-3. 2008
  36. ncbi request reprint Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation
    Margaret C Fang
    Division of General Internal Medicine, Hospitalist Group, University of California, San Francisco, San Francisco 94143, USA
    Ann Intern Med 141:745-52. 2004
    ..However, higher intensities increase hemorrhage risk. Optimal use of warfarin for atrial fibrillation requires precise information on the risk for intracranial hemorrhage as a function of patient age and anticoagulation intensity...
  37. ncbi request reprint Paracetamol (acetaminophen) and warfarin interaction: unraveling the pivotal role of the vitamin K cycle
    Elaine M Hylek
    Thromb Haemost 92:672-3. 2004